Search





Search





Insmed discontinues development of skin condition drug

ReutersApr 7, 2026 8:06 PM

April 7 (Reuters) - Insmed INSM.O said on Friday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

Is Bitcoin Reaching a Local Top? Institutional Demand vs. Retail Sentiment at $70,000

Retail investors offloaded 62,000 BTC during Bitcoin’s price weakness, while institutions accumulated 69,000 BTC over the same period, potentially signaling the onset of a "slow bull" market.

Anthropic Revenue Surpasses OpenAI for First Time, IPO as Early as October

TradingKey - April 7, 2026, Anthropic released two major updates: **Stellar Performance:** Annualized revenue surpassed $30 billion, exceeding OpenAI’s $25 billion, making it the world's highest-earning AI unicorn. **Computing Power Secured:** Reached new agreements with Broadcom and Google to sec

Meta Is About to Launch a Consumer-Facing AI Model, and OpenAI Is About to Have Its IPO, Making Now a Good Time to Buy Meta Stock

TradingKey - As of April 07, 2026, the stock price of Meta Platforms, Inc. (NASDAQ:META) is approximately $573. The second half of 2025 was a great period for this stock as it increased nearly 12%. However, in Q1 of 2026, Meta's stock dropped 13.5%, which was the largest decline since Q4 of 2022.

Tesla’s Risk: Why the SpaceX IPO and Robotaxi Uncertainty Will Threaten TSLA Stock

TradingKey - Tesla (TSLA) now has two competing narratives tugging at investors' interests in somewhat opposite directions. The first is that the expected Tesla Robotaxi experience is baked into Tesla's valuation, but regulatory developments have raised questions over when and if the Tesla Robotaxi

JPMorgan Warns Tesla Shares Could Fall Another 60%, Can Musk Still Turn the Tide?

TradingKey - JPMorgan (JPM) issued a red warning for Tesla (TSLA) in its latest research report. Analyst Ryan Brinkman lowered the stock's year-end price target to $145, implying that Tesla could face a plunge of nearly 60% from its current share price of approximately $352.

Tradingkey

KeyAI

